#1 Clinical Trials Search in Europe

Study on Preventing Cytomegalovirus Infection in Stem Cell Transplant Patients Using Cytolytic T Lymphocytes

2 1 1 1

What is this study about?

This clinical trial is focused on preventing Cytomegalovirus (CMV) infection in patients who have undergone a specific type of stem cell transplant known as hematopoietic stem cell transplantation (HSCT). This procedure is often used to treat various blood-related conditions, including some cancers. The study is particularly aimed at patients who have received transplants from family members with matching tissue types, known as HLA-identical familial donors, and who do not have any specific medication available to prevent CMV infection.

The treatment being studied involves the use of advanced cellular immunotherapy, specifically with Cytolytic T Lymphocytes (CTLs). These are special immune cells that can target and destroy virus-infected cells. The purpose of the study is to evaluate how effective this treatment is in reducing the occurrence of CMV infection within the first 100 days after the transplant. This is compared to historical data from similar patients who did not receive this treatment.

Participants in the study will receive the CTL treatment through an injection. The study will monitor the incidence of CMV infection and assess the need for further CMV treatment. It will also evaluate the presence of specific immune cells that remember the CMV virus, known as CMV-specific memory T lymphocytes. The study aims to provide valuable insights into the potential benefits of using CTLs for preventing CMV infections in this patient group.

1 joining the study

Upon joining the study, the patient must have received a hematopoietic stem cell transplant from a family donor who is a perfect match in terms of human leukocyte antigen (HLA).

The donor must be screened and meet specific criteria, including being seropositive for cytomegalovirus (CMV).

The patient must have a partial recovery of the hematopoietic implant, indicated by a specific count of neutrophils in the blood.

2 initial assessment

An initial assessment will be conducted to ensure the patient meets all inclusion criteria, such as being over 18 years old and having signed a written informed consent.

A negative pregnancy test is required for women.

3 treatment phase

The patient will receive antiviral prophylaxis with specific cytotoxic T lymphocytes (CTLs) to prevent CMV infection.

This treatment aims to reduce the incidence of CMV infection within 100 days after the transplant.

4 monitoring and follow-up

The patient’s health will be monitored regularly to assess the presence of CMV infection, which is determined by measuring the viral load in the blood.

The primary goal is to evaluate the efficacy of the treatment by checking the incidence of CMV infection at 100 days post-transplant.

5 evaluation of outcomes

The study will assess the need for additional CMV treatment and evaluate the incidence of CMV-related disease.

The presence of CMV-specific memory T lymphocytes will also be assessed as part of the study’s secondary objectives.

Who Can Join the Study?

  • Adult patients over 18 years old, whether or not they have a blood-related cancer, who have received a transplant of blood-forming cells from a family donor with matching tissue type.
  • The donor will be checked to make sure they are suitable according to the criteria for blood-forming cell donors.
  • The donor must also sign a written agreement to participate before being included.
  • Patients who are not candidates to receive a medication called Letermovir.
  • The source of the blood-forming cells can be from the bloodstream or bone marrow.
  • Patients whose donor has been exposed to a virus called CMV (Cytomegalovirus).
  • Women must have a negative pregnancy test.
  • A written agreement to participate must be signed by the patient or their legal representative.
  • There must be some recovery of the blood-forming cells after the transplant, shown by a specific type of white blood cell count being above a certain level for at least three checks after the transplant.
  • Specific criteria for donors include being a tissue type match and having been exposed to CMV.

Who Cannot Join the Study?

  • Patients who have a different type of infection other than Cytomegalovirus (CMV). CMV is a virus that can cause illness in people with weakened immune systems.
  • Patients who have not undergone an allogeneic transplant. This is a type of transplant where the donor and recipient are different people.
  • Patients who do not have an HLA-identical familial donor. HLA stands for Human Leukocyte Antigen, which is a protein on cells that helps the immune system recognize which cells belong in the body and which do not. An HLA-identical familial donor is a family member whose HLA matches the patient’s.
  • Patients who are not within the specified age range for the study.
  • Patients who are not male or female, as the study includes both genders.
  • Patients who belong to a vulnerable population, as the study does not include vulnerable groups.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Hospital Universitario De Salamanca Salamanca Spain

Other Sites

Site Name City Country Status
Hxtgeogs Ujugtjyqiyaqh Mlavzty Di Vjxyohwtek Santander Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Spain Spain
Not yet recruiting
26.03.2022

Trial locations

CTLs (Cytotoxic T Lymphocytes) are a type of immune cell therapy used in this trial. These cells are specifically designed to target and destroy cells infected with the cytomegalovirus (CMV). The goal of using CTLs in this trial is to prevent CMV infection in patients who have undergone a hematopoietic stem cell transplant. This therapy is being tested to see if it can effectively reduce the incidence of CMV infection within 100 days after the transplant.

Investigated diseases:

Cytomegalovirus Infection – This is a viral infection caused by the cytomegalovirus, which is a type of herpesvirus. It often remains dormant in the body after the initial infection, but can reactivate, especially in individuals with weakened immune systems. In the context of post allogeneic HLA-identical familial hematopoietic stem cell transplantation, the virus can cause significant complications. The infection may manifest with symptoms such as fever, fatigue, and muscle aches, but can also affect various organs if it progresses. Monitoring and managing the viral load is crucial to prevent severe outcomes.

Trial ID:
2024-520020-28-00
Protocol code:
INMUNOCELL-CTMV
NCT ID:
NCT04056533
Trial Phase:
Phase I and Phase II (Integrated) – First administration to humans

Other Trials to Consider

  • A Study of Maribavir for Cytomegalovirus Infection in Stem Cell Transplant Patients Who Cannot Take or Did Not Tolerate Standard Treatment

    Recruiting

    2 1 1 1
    Investigated drugs:
    Italy

  • Study on Preventing CMV Infection in Low-Risk Kidney Transplant Patients Using Ganciclovir and Valganciclovir

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain